Observations placeholder
Vectibix
Identifier
020353
Type of Spiritual Experience
Background
A description of the experience
Panitumumab (INN), formerly ABX-EGF, is a fully human monoclonal antibody specific to the epidermal growth factor receptor (also known as EGF receptor, EGFR, ErbB-1 and HER1 in humans). Panitumumab is marketed as Vectibix.
It was approved by the U.S. Food and Drug Administration (FDA) for the first time in September 2006, for "the treatment of EGFR-expressing metastatic colorectal cancer with disease progression" despite prior treatment.
Side Effects
Panitumumab, like cetuximab has been associated with skin rash, fatigue, nausea, diarrhea and decreased magnesium levels. Often, skin rash is noted in the sun exposed parts of the body, such as the face or chest. Oral antibiotics may be needed for worsening skin rash, such as one accompanied with blisters and ulcers. Otherwise, topical steroid creams like hydrocortisone may help.
On Feb, 18, 2016: 1,367 people reported to have side effects when taking Vectibix. Among them, 4 people (0.29%) have Hallucination.
On Feb, 8, 2016: 1,367 people reported to have side effects when taking Vectibix. Among them, 85 people (6.22%) have Death.
Time on Vectibix when people have Death :
| < 1 month | 1 - 6 months | 6 - 12 months | 1 - 2 years | 2 - 5 years | 5 - 10 years | 10+ years | |
| Death | 31.25% | 31.25% | 28.12% | 9.38% | 0.00% | 0.00% | 0.00% |